Juan Fueyo, MD, Professor in the Department of Neuro-Oncology at MD Anderson Cancer Center, gave an oral presentation of clinical results showing that DNX-2401 therapy for high grade malignant glioma leads to a reduction in the expression of TIM3, a key marker of T-cell exhaustion and negative regulator of antitumor immunity.
| |
| [20-November-2017] |
| HOUSTON, Nov. 20, 2017 /PRNewswire/ -- DNAtrix, a leader in the development of oncolytic virus immunotherapies for cancer, announced multiple studies detailing the mechanism and efficacy of DNX-2401 were presented at the 2017 Society for Neuro-Oncology (SNO) Annual Meeting, held in San Francisco, CA on November 16th - 19th. Juan Fueyo, MD, Professor in the Department of Neuro-Oncology at MD Anderson Cancer Center, gave an oral presentation of clinical results showing that DNX-2401 therapy for high grade malignant glioma leads to a reduction in the expression of TIM3, a key marker of T-cell exhaustion and negative regulator of antitumor immunity. These results are consistent with DNX-2401 triggering an anti-tumor immune response in patients. Additional results were presented by scientists and physicians from Erasmus MC (Rotterdam, Netherlands) and Clínica Universidad de Navarra (Pamplona, Spain), demonstrating that DNX-2401 treatment promotes a microenvironment that is detrimental to tumors and is efficacious in a model of pediatric central nervous system tumors, a devastating disease in children. “We are excited that this important research was selected for presentation at SNO, the premier conference for neuro-oncology,” said Frank Tufaro, PhD, CEO of DNAtrix. “These results are encouraging and provide further support for the use of our lead product, DNX-2401, in combination with immunotherapeutic agents such as checkpoint inhibitors, a clinical study which is in progress.” Details of the presentations on DNX-2401 (also known as Delta-24-RGD) are as follows: Immunomarkers in the DNX-2401 (Delta-24-RGD) oncolytic virus Phase I clinical trial Abstract Number: ATIM-08 Oncolytic viral therapy with Delta-24-RGD induces a tumor-detrimental environment via phenotypic shift of macrophages Abstract Number: TMIC-03 The oncolytic adenovirus Delta-24-RGD mediates an efficient antitumor response in vivo in supratentorial primitive neuroectodermal tumors Abstract Number: PDTM-12 For more information about ongoing DNAtrix clinical studies, visit the ClinicalTrials.gov website: NCT02798406 (DNX-2401 + KEYTRUDA for recurrent glioblastoma) and NCT03178032 (DNX-2401 for newly diagnosed pediatric diffuse intrinsic pontine glioma). About DNX-2401 About DNAtrix Contact
View original content:http://www.prnewswire.com/news-releases/mechanism-of-action-studies-for-dnatrixs-oncolytic-virus-dnx-2401-presented-at-the-2017-society-for-neuro-oncology-annual-meeting-300559158.html SOURCE DNAtrix |
